333: Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases  by Agura, E.D. et al.
Poster Session II 123333
PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINE WITH
PARENTERAL BUSULFAN FOLLOWED BY ALLOGENEIC RELATED OR UN-
RELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF HEMA-
TOLOGIC MALIGNANCIES AND DISEASES
Agura, E.D., Berryman, R.B., Fay, J.W., Pineiro, L.A., Vance, E.A.,
Tadic-Ovcina, M. Charles A. Sammons Cancer Center, Dallas, TX.
Background: Nonablative transplant regimens are useful to treat
patients who are elderly or too ill to undergo a full-intensity ablative
allogeneic transplant regimen. However, this approach is limited by
a higher relapse rate in some situations. We developed a novel con-
ditioning regimen using the nucleoside analogue clofarabine (CLO)
with busulfan (BU) to treat elderly patients with acute leukemia or
high risk MDS who are not in remission or are at high risk of re-
lapse. Methods: Seven patients were enrolled on this single institu-
tion; phase II, IRB-approved trial, so far. The diagnoses at the time
of transplant were four with AML, one with ALL, and two with
MDS. At the time of study entry, six patients had persistent/relapsed
disease and one was in remission. All patients received CLO 40 mg/
m2/day iv on d-8 through d-4 followed by BU 3.2 mg/m2/day iv on
d-3 and -2, followed by infusion of HLA matched related or unre-
lated donor PBSC on day 0. GVHD prophylaxis consisted of oral
FK506 and MTX 5 mg/m2 iv d1 1,13 and16. BU and CLO phar-
macokinetic samples were collected on all patients for later PK anal-
ysis. Results: Primary endpoints included toxicity and response to
therapy. There were no cases of hepatic, cardiac, or renal toxicity at-
tributed to the conditioning regimen by d1 30. Acute toxicities in-
cluded hand/foot syndrome, n5 2 (one grade 1, and one grade 3 by
CTCAE v 3.0); fluid retention, n5 3 (2 grade 1 and 1 grade 2); nau-
sea n5 5 (four grade 1 and 1 gr 2). One subject suffered respiratory
failure of unknown etiology. That resolved completely and was
deemed to be possibly related to the treatment. All patients had he-
matologic nadirs lasting 12 to 15 days. GCSF was used in 6 of 7 sub-
jects. 7 of 7 patients achieved allogeneic engraftment with myeloid
cells by day130. Response to therapy was documented in 5 patients
by d1 30, two are not yet evaluated. One (1) patient relapsed by d1
62, one relapsed by day154. 3 of 5 remain in remission with follow
up ranging from 91 to 152 days.Conclusions:CLO1BU is a novel
allogeneic conditioning regimen that seems to be well tolerated by
the small number of subjects treated so far at our institution. The
follow up is not long enough to conclude more at this time. The
study continues to accrue patients and will be updated at the meet-
ing.334
NON-MYELOABLATIVE TRANSPLANTATION IS A FEASIBLE OPTION IN
PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES: A SIN-
GLE CENTER EXPERIENCE
Ganguly, S., Vaka, S., Divine, C.L., Deauna-Limayo, D.,
Bodensteiner, D.C., Skikne, B.S. University of Kansas Medical Center,
Kansas City, KS.
Introduction: There are limited therapeutic options in patients
with advanced hematologic diseases. Historically patients with re-
lapsed/refractory disease do not fare well after non-myeloablative
allogeneic stem cell transplantation (NST). Methods: In an at-
tempt to examine whether NST provides disease control in patients
with high risk hematologic malignancies, we retrospectively evalu-
ated our experience and analyzed the outcomes of NST in patients
with high risk hematologic malignancies from 1999 to 2006. Re-
sults: Ten males and 4 females (n 5 14) of median age 48 years
(range: 19–65 years) were treated. Of these, only 4 patients were
in complete remission (CR) at the time of transplantation and 10 pa-
tients were transplanted with active disease. All patients (n 5 4) in
CR at the time of transplantation had received one or two prior
myeloablative stem cell transplantation. The majority of patients re-
ceived peripheral blood stem cells (n 5 12). One patient received
bone marrow and one patient received cord blood derived stem
cells. All patients engrafted. Median time for neutrophil recovery
was 18 days (range: 10–29 days) and 22 days (range: 14–47 days)
for platelets. In two patients, the platelet count did not drop below
20 103/ml and two patients died prior to platelet engraftment. Me-dian duration of follow-up for those who did not succumb to early
transplant-related mortality (\100 days) was 5.2 months (range:
105 days-2 years). Median survival time of this cohort was 125
days. Of the 14 patients, 9 have died. Four patients (30%) died
within 100-days of transplantation. Overall survival (OS) of all pa-
tients who did not succumb to TRM was 44% at 14 months. No re-
lapse occurred after 6 months. All 5 patients that are alive have
chronic graft versus host disease. OS in patients transplanted in
CR (n5 4) at 1-year was 50%, and was 44% for those transplanted
with active disease (n 5 10). Disease status at transplantation was
not a significant variable for survival (p5 0.88). Most frequent cause
of death was relapse/progression of disease (n 5 5; 55%). Conclu-
sion: In conclusion, NST provides a possible therapeutic option in
a proportion of patients with high risk hematologic malignancies.
Disease relapse prior to development of graft versus tumor effect re-
mains the most frequent cause of failure in patients transplanted
with active disease.335
RADIATION FOLLOWED BY MYLOTARG PLUS DLI FOR EXTRAMEDUL-
LARY RELAPSE FROM ACUTE MYELOID LEUKEMIA POST-ALLOGENEIC
TRANSPLANT
Sharma, M., Cumpston, A., Craig, M. West Virginia University, Mor-
gantown, WV.
Introduction: Extramedullary relapse of acute leukemia after he-
matopoietic cell transplant can occur in the form of granulocytic sar-
comas and leukemia cutis. According to some published reports,
they may occur in up to 20% of post-transplant patients. The treat-
ment of these relapses has been center dependent, and no treatment
protocol has been published which clearly shows superiority. We
describe three patients with extramedullary relapse who were treated
with a combination of radiation, gemtuzumab ozogamicin and DLI
(donor leukocyte infusion). Methods: All three patients had a diag-
nosis of AML and had induction and consolidation therapy, fol-
lowed by a myeloablative transplant with cytoxan and TBI as
a preparative regimen. Two patients presented with chloromas
and one presented with leukemia cutis as sites of recurrence.
None had evidence of bone marrow recurrence, and relapse oc-
curred from 4 – 11 months post transplant. All three were treated
with focal radiation therapy to the site of relapse followed by gem-
tuzumab ozogamicin and DLI. The radiation doses were 20–30 Gy,
followed by gemtuzumab ozogamicin 9 mg/m2 given every two
weeks for two doses. All three patients received DLI initially at
1.0  10–7 CD31 cells/kg, and subsequently dose-escalated to
2.0  10–7. Results: All three patient achieved disease response.
Median disease free survival has not been reached. One patient
with leukemia cutis died of complication from acute GVHD 9
months after the first dose of DLI. The remaining two patients
with chloromas are still alive and free of marrow relapse after two
doses of DLI. Conclusion: The combination of focal radiation fol-
lowed by gemtuzumab ozogamicin (9 mg/m2) every two weeks for
two doses, followed by dose escalating DLI is an option for patients
with extramedullary relapse of acute leukemia following hemato-
poietic cell transplantation.GVH/GVL336
RELATIVE CONTRIBUTION OF CD127 NEGATIVE SELECTION, RAPAMY-
CIN, ANDTGF-b TO THEGENERATIONOFHUMANREGULATORY T CELLS
THAT INHIBIT ALLOREACTIVITY VIA DENDRITIC CELL MODULATION
Amarnath, S.1, Foley, J.1, Mariotti, J.1, Costanzo, C.M.1, Ryan, K.1,
Fong, T.2, Warner, N.2, Fowler, D.H.1. 1Center for Cancer Research,
National Cancer Institute, National Institute of Health, Bethesda, MD;
2BD Biosciences, San Jose, CA.
Regulatory T cells (Tregs) express reduced IL-7Ra (CD127) and
preferentially expand in rapamycin or TGF-b. Here, we evaluated
the independent and combined effect of CD127 negative selection,
